The arrival of a new self-injectable biosimilar used to treat rheumatoid arthritis has prompted a leading Australian gastroenterologist to remind clinicians of the importance of checking the ‘brand substitution not permitted’ box on prescriptions. The move will prevent switching between biosimilars and biologic without the clinician’s involvement. This process known as ‘a flagging’ has attracted ...
Clinicians reminded to tick box to avoid unapproved biosimilar switching
By Amanda Sheppeard
25 Oct 2016